{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:17:36Z","timestamp":1763036256612},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2000,5]]},"DOI":"10.1007\/s11940-000-0006-1","type":"journal-article","created":{"date-parts":[[2007,6,4]],"date-time":"2007-06-04T17:43:56Z","timestamp":1180979036000},"page":"231-241","source":"Crossref","is-referenced-by-count":7,"title":["Myoclonus"],"prefix":"10.1007","volume":"2","author":[{"given":"Steven","family":"Frucht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"6_CR1","first-page":"196","volume-title":"Movement Disorders","author":"CD Marsden","year":"1982","unstructured":"Marsden CD, Hallett M, Fahn S: The nosology and pathophysiology of myoclonus. In Movement Disorders. Edited by Marsden CD, Fahn S. London: Butterworth Scientific; 1982:196\u2013248."},{"key":"6_CR2","first-page":"1","volume-title":"Advances in Neurology","author":"S Fahn","year":"1986","unstructured":"Fahn S, Marsden CD, Van Woert MH: Definition and classification of myoclonus. In Advances in Neurology, vol 43. Edited by Fahn S. New York: Raven Press; 1986:1\u20135."},{"key":"6_CR3","first-page":"247","volume-title":"Treatment of Movement Disorders","author":"EJ Pappert","year":"1995","unstructured":"Pappert EJ, Goetz CG: Treatment of myoclonus. In Treatment of Movement Disorders. Edited by Kurlan R. Philadelphia: J.B. Lippincott Co.; 1995:247\u2013336. With 687 references, this chapter is the most comprehensive review of the treatment of myoclonus."},{"key":"6_CR4","first-page":"189","volume":"3","author":"H Shibasaki","year":"1996","unstructured":"Shibasaki H: Overview and classification of myoclonus. Clin Neurosci 1996, 3:189\u2013192.","journal-title":"Clin Neurosci"},{"key":"6_CR5","unstructured":"Physicians\u2019 Desk Reference. New Jersey: Medical Economics Company; 1998:428\u2013434, 2475\u20132478."},{"key":"6_CR6","unstructured":"Personal communication."},{"key":"6_CR7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/mds.870080112","volume":"8","author":"P Brown","year":"1993","unstructured":"Brown P, Steiger MJ, Thompson PD, et al.: Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993, 8:63\u201368.","journal-title":"Mov Disord"},{"key":"6_CR8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/mds.870110615","volume":"11","author":"A Ikeda","year":"1996","unstructured":"Ikeda A, Shibasaki H, Tashiro K, et al. and the Myoclonus\/ Piracetam Study Group: Clinical trial of piracetam in patients with myoclonus: nationwide multi-institution study in Japan. Mov Disord 1996, 11:691\u2013700.","journal-title":"Mov Disord"},{"key":"6_CR9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-198602000-00006","volume":"9","author":"JA Obeso","year":"1986","unstructured":"Obeso JA, Artieda J, Luquin MR, et al.: Antimyoclonic action of piracetam. Clin Neuropharmacol 1986, 9:58\u201364.","journal-title":"Clin Neuropharmacol"},{"key":"6_CR10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00002826-198812000-00006","volume":"11","author":"JA Obeso","year":"1988","unstructured":"Obeso JA, Artieda J, Quinn N, et al.: Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol 1988, 11:529\u2013536.","journal-title":"Clin Neuropharmacol"},{"key":"6_CR11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/jnnp.64.3.344","volume":"64","author":"M Koskiniemi","year":"1998","unstructured":"Koskiniemi M, Van Vleyemen B, Hakamies L, et al.: Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicenter, randomized, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998, 64:344\u2013348. A well-designed study showing that piracetam is an effective treatment for progressive myoclonic epilepsy.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6_CR12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.410070611","volume":"7","author":"LJ Thal","year":"1980","unstructured":"Thal LJ, Sharpless NS, Wolfson L, Katzman R: Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations. Ann Neurol 1980, 7:570\u2013576.","journal-title":"Ann Neurol"},{"key":"6_CR13","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1056\/NEJM198010023031403","volume":"303","author":"EM Sternberg","year":"1980","unstructured":"Sternberg EM, Van Woert MH, Young SN, et al.: Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med 1980, 303:782\u2013787.","journal-title":"N Engl J Med"},{"key":"6_CR14","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1001\/jama.1992.03490140032012","volume":"14","author":"SL Nightingale","year":"1992","unstructured":"Nightingale SL: From the Food and Drug Administration. JAMA 1992, 14:1828.","journal-title":"JAMA"},{"key":"6_CR15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1528-1157.1995.tb01615.x","volume":"36","author":"MT Pranzatelli","year":"1995","unstructured":"Pranzatelli MT, Tate E, Huang Y, et al.: Neuropharmacology of progressive myoclonic epilepsy: response to 5-hydroxy-L-tryptophan. Epilepsia 1995, 36:783\u2013791.","journal-title":"Epilepsia"},{"key":"6_CR16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/brain\/86.1.111","volume":"86","author":"JW Lance","year":"1963","unstructured":"Lance JW, Adams RD: The syndrome of intention or action myoclonus as a sequel to hypoxic encephalopathy. Brain 1963, 86:111\u2013136.","journal-title":"Brain"},{"key":"6_CR17","first-page":"49","volume-title":"Advances in Neurology","author":"S Fahn","year":"1979","unstructured":"Fahn S: Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. In Advances in Neurology, vol 26. Edited by Fahn S. New York: Raven Press; 1979:49\u201384."},{"key":"6_CR18","first-page":"157","volume-title":"Advances in Neurology","author":"S Fahn","year":"1986","unstructured":"Fahn S: Posthypoxic action myoclonus: literature review update. In Advances in Neurology, vol 43. Edited by Fahn S. New York: Raven Press; 1986:157\u2013169."},{"key":"6_CR19","doi-asserted-by":"crossref","unstructured":"Frucht S, Fahn S: The clinical spectrum of posthypoxic myoclonus. Mov Disord 2000, in press.","DOI":"10.1002\/mds.870150702"},{"key":"6_CR20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1001\/archneur.1982.00510160042008","volume":"39","author":"M Iivanainen","year":"1982","unstructured":"Iivanainen M, Himberg J: Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy. Arch Neurol 1982, 39:236\u2013238.","journal-title":"Arch Neurol"},{"key":"6_CR21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00002826-199210000-00007","volume":"15","author":"J Vaamonde","year":"1992","unstructured":"Vaamonde J, Legarda I, Jimenez-Jimenez J, Obeso JA: Acetazolamide improves action myoclonus in Ramsay Hunt syndrome. Clin Neuropharmacol 1992, 15:392\u2013396.","journal-title":"Clin Neuropharmacol"},{"key":"6_CR22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870110202","volume":"11","author":"NP Quinn","year":"1996","unstructured":"Quinn NP: Essential myoclonus and myoclonic dystonia. Mov Disord 1996, 11:119\u2013124.","journal-title":"Mov Disord"},{"key":"6_CR23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1600-0404.1985.tb00860.x","volume":"72","author":"G Lundemo","year":"1985","unstructured":"Lundemo G, Persson HE: Hereditary essential myoclonus. Acta Neurol Scand 1985, 72:176\u2013179.","journal-title":"Acta Neurol Scand"},{"key":"6_CR24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mds.870060308","volume":"6","author":"S Fahn","year":"1991","unstructured":"Fahn S, Sjaastad O: Hereditary essential myoclonus in a large Norwegian family. Mov Disord 1991, 6:237\u2013247.","journal-title":"Mov Disord"},{"key":"6_CR25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00002826-198406000-00004","volume":"7","author":"R Duvoisin","year":"1984","unstructured":"Duvoisin R: Essential myoclonus: response to anticholinergic therapy. Clin Neuropharmacol 1984, 7:141\u2013147.","journal-title":"Clin Neuropharmacol"},{"key":"6_CR26","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1176\/ajp.142.11.1368","volume":"142","author":"TJ Ives","year":"1985","unstructured":"Ives TJ, Fleming MF, Weart CW, Bloch D: Treatment of intractable hiccups with intramuscular haloperidol. Am J Psychiatry 1985, 142:1368\u20131369.","journal-title":"Am J Psychiatry"},{"key":"6_CR27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJM198607033150114","volume":"315","author":"R Stalnikowicz","year":"1986","unstructured":"Stalnikowicz R, Fich A, Troudart T: Amitriptyline for intractable hiccups. N Engl J Med 1986, 315:64\u201365.","journal-title":"N Engl J Med"},{"key":"6_CR28","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1212\/WNL.31.11.1458","volume":"31","author":"PL Jacobson","year":"1981","unstructured":"Jacobson PL, Messenheimer JA, Farmer TW: Treatment of intractable hiccups with valproic acid. Neurology 1981, 31:1458\u20131460.","journal-title":"Neurology"},{"key":"6_CR29","first-page":"1789","volume":"87","author":"FC Ramirez","year":"1992","unstructured":"Ramirez FC, Graham DY: Treatment of intractable hiccup with baclofen: results of a double-blind randomized, controlled, cross-over study. Am J Gastroenterol 1992, 87:1789\u20131791.","journal-title":"Am J Gastroenterol"},{"key":"6_CR30","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1056\/NEJM198810133191501","volume":"319","author":"AM Burke","year":"1988","unstructured":"Burke AM, White AB, Brill N: Baclofen for intractable hiccups [letter]. N Engl J Med 1988, 319:1354.","journal-title":"N Engl J Med"},{"key":"6_CR31","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/brain\/113.6.1645","volume":"113","author":"G Deuschl","year":"1990","unstructured":"Deuschl G, Mischke G, Schenck E, et al.: Symptomatic and essential rhythmic palatal myoclonus. Brain 1990, 113:1645\u20131672. The classic paper defining the natural history of palatal myoclonus.","journal-title":"Brain"},{"key":"6_CR32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ana.410100427","volume":"10","author":"JM Ferro","year":"1981","unstructured":"Ferro JM, Castro-Caldas A: Palatal myoclonus and carbamazepine. Ann Neurol 1981, 10:402.","journal-title":"Ann Neurol"},{"key":"6_CR33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mds.870020202","volume":"2","author":"B Jabbari","year":"1987","unstructured":"Jabbari B, Rosenberg M, Scherokman B, et al.: Effectiveness of trihexyphenidyl against pendular nystagmus and palatal myoclonus: evidence of cholinergic dysfunction. Mov Disord 1987, 2:93\u201398.","journal-title":"Mov Disord"},{"key":"6_CR34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000113180","volume":"38","author":"R Cakmor","year":"1977","unstructured":"Cakmor R, Idiman E, Idiman F, et al.: Essential palatal tremor successfully treated with flunarizine. Eur Neurol 1977, 38:133\u2013134.","journal-title":"Eur Neurol"},{"key":"6_CR35","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/mds.870110628","volume":"11","author":"B Scott","year":"1996","unstructured":"Scott B, Evans RW, Jankovic J: Treatment of palatal myoclonus with sumatriptan. Mov Disord 1996, 11:748\u2013751.","journal-title":"Mov Disord"},{"key":"6_CR36","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0194-5998(96)70194-8","volume":"114","author":"SM Varney","year":"1996","unstructured":"Varney SM, Demetroulakos JL, Fletcher MH, et al.: Palatal myoclonus: treatment with Clostridium botulinum toxin injection. Otolaryngol Head Neck Surg 1996, 114:317\u2013320.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"6_CR37","first-page":"213","volume":"27","author":"GE Bryce","year":"1998","unstructured":"Bryce GE, Morrison MD: Botulinum toxin treatment of essential palatal myoclonus tinnitus. J Otol 1998, 27:213\u2013216.","journal-title":"J Otol"},{"key":"6_CR38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-2008-1040955","volume":"16","author":"L Averbuch-Heller","year":"1996","unstructured":"Averbuch-Heller L, Remler B: Opsoclonus. Semin Neurol 1996, 16:21\u201326.","journal-title":"Semin Neurol"},{"key":"6_CR39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1056\/NEJM199501193320317","volume":"332","author":"M Nitschke","year":"1995","unstructured":"Nitschke M, Hochberg F, Dropcho E: Improvement of paraneoplastic opsoclonus-myoclonus after protein A column therapy [letter]. N Engl J Med 1995, 332:192.","journal-title":"N Engl J Med"},{"key":"6_CR40","first-page":"197","volume":"144","author":"P Brown","year":"1991","unstructured":"Brown P, Thompson PD, Rothwell JC, et al.: Axial myoclonus of propriospinal origin. Brain 1991, 144:197\u2013214.","journal-title":"Brain"},{"key":"6_CR41","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/archneur.1986.00520100039012","volume":"43","author":"J Jankovic","year":"1986","unstructured":"Jankovic J, Pardo R: Segmental myoclonus: clinical and pathologic study. Arch Neurol 1986, 43:1025\u20131031.","journal-title":"Arch Neurol"},{"key":"6_CR42","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","volume":"48","author":"J Jankovic","year":"1997","unstructured":"Jankovic J, Beach J: Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997, 48:358\u2013362.","journal-title":"Neurology"},{"key":"6_CR43","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00002826-199104000-00009","volume":"14","author":"FJ Jimenez-Jimenez","year":"1991","unstructured":"Jimenez-Jimenez FJ, Roldan A, Zancada F, et al.: Spinal myoclonus: successful treatment with the combination of sodium valproate and L-5-hydroxytryptophan. Clin Neuropharmacol 1991, 14:186\u2013190.","journal-title":"Clin Neuropharmacol"},{"key":"6_CR44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/mds.870090221","volume":"9","author":"KB Polo","year":"1994","unstructured":"Polo KB, Jabbari B: Effectiveness of botulinum toxin type A against painful limb myoclonus of spinal cord origin. Mov Disord 1994, 9:233\u2013235.","journal-title":"Mov Disord"},{"key":"6_CR45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/1531-8257(199901)14:1<182::AID-MDS1040>3.0.CO;2-8","volume":"14","author":"A Lagueny","year":"1999","unstructured":"Lagueny A, Tison F, Burbaud P, et al.: Stimulussensitive spinal segmental myoclonus improved with injections of botulinum toxin type A. Mov Disord 1999, 14:182\u2013185.","journal-title":"Mov Disord"},{"key":"6_CR46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/mds.870090511","volume":"9","author":"P Brown","year":"1994","unstructured":"Brown P, Rothwell JC, Thompson PD, Marsden CD: Propriospinal myoclonus: evidence for spinal \u201cpattern\u201d generators in humans. Mov Disord 1994, 9:571\u2013576.","journal-title":"Mov Disord"},{"key":"6_CR47","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1212\/WNL.42.8.1591","volume":"42","author":"S Chokroverty","year":"1992","unstructured":"Chokroverty S, Walters A, Zimmerman T, Picone M: Propriospinal myoclonus: a neurophysiologic analysis. Neurology 1992, 42:1591\u20131595.","journal-title":"Neurology"},{"key":"6_CR48","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0025-6196(12)65163-5","volume":"65","author":"BR Krueger","year":"1990","unstructured":"Krueger BR: Restless legs syndrome and periodic movements of sleep. Mayo Clin Proc 1990, 65:999\u20131006.","journal-title":"Mayo Clin Proc"},{"key":"6_CR49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF02191538","volume":"245","author":"J Staedt","year":"1995","unstructured":"Staedt J, Stoppe G, Kogler A, et al.: Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration. Eur Arch Psychiatry Clin Neurosci 1995, 245:8\u201310.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"6_CR50","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1212\/WNL.35.3.408","volume":"35","author":"N Ohanna","year":"1985","unstructured":"Ohanna N, Peled R, Rubin A, et al.: Periodic leg movements in sleep: effect of clonazepam treatment. Neurology 1985, 35:408\u2013411.","journal-title":"Neurology"},{"key":"6_CR51","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/sleep\/9.3.385","volume":"9","author":"MM Mitler","year":"1986","unstructured":"Mitler MM, Browman CP, Menn SJ, et al.: Nocturnal myoclonus: treatment efficacy of clonazepam and temazepam. Sleep 1986, 9:385\u2013392.","journal-title":"Sleep"},{"key":"6_CR52","first-page":"112","volume":"14","author":"W Hening","year":"1983","unstructured":"Hening W, Walter A, Cote L, Fahn S: Opiate responsive myoclonus [abstract]. Ann Neurol 1983, 14:112.","journal-title":"Ann Neurol"},{"key":"6_CR53","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archneur.1982.00510230065027","volume":"39","author":"S Akpinar","year":"1982","unstructured":"Akpinar S: Treatment of restless leg syndrome with levodopa plus benserazide [letter]. Arch Neurol 1982, 39:739.","journal-title":"Arch Neurol"},{"key":"6_CR54","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/00002826-198610000-00006","volume":"9","author":"J Montplaisir","year":"1986","unstructured":"Montplaisir J, Godbout R, Poirier G, Bedard MA: Restless legs syndrome and periodic movements in sleep: pathophysiology and treatment with L-dopa. Clin Neuropharmacol 1986, 9:456\u2013463.","journal-title":"Clin Neuropharmacol"},{"key":"6_CR55","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1212\/WNL.38.12.1845","volume":"38","author":"C Brodeur","year":"1988","unstructured":"Brodeur C, Montplaiser J, Godbout R, Marinier R: Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988, 38:1845\u20131848.","journal-title":"Neurology"},{"key":"6_CR56","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/sleep\/18.8.681","volume":"18","author":"C Trenkwalder","year":"1995","unstructured":"Trenkwalder C, Stiasny K, Pollmacher T, et al.: L-Dopa therapy of uremic and idopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995, 18:681\u2013688.","journal-title":"Sleep"},{"key":"6_CR57","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.410240318","volume":"24","author":"AS Walters","year":"1988","unstructured":"Walters AS, Hening WA, Kavey N, et al.: A double blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988, 24:455\u2013458.","journal-title":"Ann Neurol"},{"key":"6_CR58","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/BF01277664","volume":"104","author":"J Staedt","year":"1997","unstructured":"Staedt J, Wassmuth F, Ziemann U, et al.: Pergolide: treatment of choice in restless leg syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-dopa. J Neural Transm 1997, 104:461\u2013468. An important study that suggests that dopamine agonists should be used first in the treatment of restless leg syndrome.","journal-title":"J Neural Transm"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-000-0006-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-000-0006-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-000-0006-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:56:42Z","timestamp":1559437002000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-000-0006-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["6"],"URL":"https:\/\/doi.org\/10.1007\/s11940-000-0006-1","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}